Van ECK Associates Corp Raises Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Van ECK Associates Corp boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 31.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,996 shares of the medical equipment provider's stock after acquiring an additional 18,524 shares during the period. Van ECK Associates Corp owned 0.11% of Lantheus worth $6,888,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus during the 3rd quarter valued at $25,000. Signaturefd LLC lifted its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the last quarter. RiverPark Advisors LLC bought a new stake in Lantheus in the 3rd quarter worth about $74,000. Finally, CWM LLC increased its holdings in Lantheus by 63.0% in the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock worth $82,000 after buying an additional 290 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LNTH shares. Truist Financial restated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target for the company. Finally, JMP Securities reiterated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $131.86.

Remove Ads

Lantheus Stock Performance

Shares of NASDAQ LNTH traded down $2.61 during midday trading on Friday, reaching $78.23. The stock had a trading volume of 899,189 shares, compared to its average volume of 803,847. The company has a market capitalization of $5.44 billion, a price-to-earnings ratio of 13.02 and a beta of 0.44. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The stock has a 50-day moving average of $90.31 and a 200-day moving average of $97.06.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.